Therapeutic effects of genistein in experimentally induced ulcerative colitis in rats via affecting mitochondrial biogenesis
- PMID: 37084167
- DOI: 10.1007/s11010-023-04746-8
Therapeutic effects of genistein in experimentally induced ulcerative colitis in rats via affecting mitochondrial biogenesis
Abstract
Ulcerative colitis (UC) is an inflammatory bowel disease that affects the mucosa of the colon, resulting in severe inflammation and ulcers. Genistein is a polyphenolic isoflavone present in several vegetables, such as soybeans and fava beans. Therefore, we conducted the following study to determine the therapeutic effects of genistein on UC in rats by influencing antioxidant activity and mitochondrial biogenesis and the subsequent effects on the apoptotic pathway. UC was induced in rats by single intracolonic administration of 2 ml of 4% acetic acid. Then, UC rats were treated with 25-mg/kg genistein. Colon samples were obtained to assess the gene and protein expression of nuclear factor erythroid 2-related factor-2 (Nrf2), heme oxygenase-1 (HO-1), peroxisome proliferator-activated receptor-gamma coactivator (PGC-1), mitochondrial transcription factor A (TFAM), B-cell lymphoma 2 (BCL2), BCL2-associated X (BAX), caspase-3, caspase-8, and caspase-9. In addition, colon sections were stained with hematoxylin/eosin to investigate the cell structure. The microimages of UC rats revealed inflammatory cell infiltration, hemorrhage, and the destruction of intestinal glands, and these effects were improved by treatment with genistein. Finally, treatment with genistein significantly increased the expression of PGC-1, TFAM, Nrf2, HO-1, and BCL2 and reduced the expression of BAX, caspase-3, caspase-8, and caspase-9. In conclusion, genistein exerted therapeutic effects against UC in rats. This therapeutic activity involved enhancing antioxidant activity and increasing mitochondrial biogenesis, which reduced cell apoptosis.
Keywords: B-cell lymphoma 2 (BCL2); BCL2-associated X (BAX); Heme Oxygenase-1 (HO-1); Mitochondrial transcription factor A (TFAM); Nuclear factor erythroid 2-related factor-2 (Nrf2); Peroxisome proliferator-activated receptor-gamma coactivator (PGC-1).
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Adams SM, Bornemann PH (2013) Ulcerative colitis. Am Fam Physician 87:699–705 - PubMed
-
- Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ (2012) Ulcerative colitis. Lancet 380:1606–1619. https://doi.org/10.1016/S0140-6736(12)60150-0 - DOI - PubMed
-
- Armuzzi A, Liguori G (2021) Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Dig Liver Dis 53:803–808. https://doi.org/10.1016/j.dld.2021.03.002 - DOI - PubMed
-
- Colombel JF, Mahadevan U (2017) Inflammatory bowel disease 2017: innovations and changing paradigms. Gastroenterology 152:309–312. https://doi.org/10.1053/j.gastro.2016.12.004 - DOI - PubMed
-
- Gardiner LJ, Carrieri AP, Bingham K, Macluskie G, Bunton D, McNeil M, Pyzer-Knapp EO (2022) Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease. PLoS ONE 17:e0263248. https://doi.org/10.1371/journal.pone.0263248 - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
